We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 91.00 | 1.20 | 1.60 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/8/2020 21:27 | Zak Mir chart forecast 35p by end of next month https://www.share-ta | terry508 | |
07/8/2020 08:19 | What this morning RNS means is FDA IND, huge appointment, also means Chemerin is going to take USA. This is heading for 40pDr Khodabakhsh is also managing partner of Specialty Surgical Centre which is the largest centre dedicated to eye surgery in the western US. He is a consultant and speaker for Johnson and Johnson, Bausch and Lomb, Shire, Novartis, sun pharmaceuticals, Omeros.Dr A. James Khodabakhsh MD. His appointment is effectively immediately, with the remit to bring together a small group of leaders-in-the-field to review and inform the Company's plans to progress its lead product candidate, Chemerin, to an IND in the indication of dry-eye disease. | albert arthur | |
07/8/2020 06:58 | You're not wrong p5tvr, the clue is ins " Okyo shares have been surging" good job he's not a real stockmarket player. | tracy_moore | |
07/8/2020 00:06 | 2-4 bagger? https://twitter.com/ | terry508 | |
06/8/2020 15:06 | Jim Mellon has just dumped his entire stake in tiddler Okyo Pharma, which is developing therapies for inflammatory eye diseases and chronic pain management. Below is a link to the announcement that shows he went down from owning just over 4pc to almost 0. Now, that does seem a strange move by Mellon - a 'billionaire' investor that is said to be friends with Brexit leader Aaron Banks - given Okyo shares have been surging in recent weeks to almost 17p. Watching... | spurs90 | |
05/8/2020 01:06 | https://www.proactiv | jungmana | |
04/8/2020 16:03 | Nice dip so bought a few more at 14.77p | volsung | |
03/8/2020 19:14 | I've got quite a nice one. | albert arthur | |
03/8/2020 14:00 | Look at the £18k buys from this morning. Who is building a hefty stake here? | intheknow69 | |
03/8/2020 13:48 | 4billion revenue dry eye market, OKYO believe they could take out the market leader:Watch Kunwar speak about it here:https://youtu.b | albert arthur | |
03/8/2020 13:41 | fiddley always does | tracy_moore | |
03/8/2020 10:08 | Oh dear...Looks like apfindley MISSED the boat...LOFL | p5tvr | |
03/8/2020 10:02 | Oh dear. And its not even a covid pharma stock.I guess people continue to follow twitter pumpers | apfindley | |
03/8/2020 08:15 | OKYO now tops my SIPP | volsung | |
03/8/2020 08:09 | This I like. Other shares not so. I will not drink today because monday but is good anyway thinks I | volsung | |
02/8/2020 19:56 | Maybe.... And name it tiziana 2.0 | kasspass | |
02/8/2020 19:31 | It's got to be the only TILS board member that's missing? | terry508 | |
02/8/2020 16:37 | A well respect heathcare executive, as the mail on Sunday understands, is close to joining the company.There must be a good reason for that. | kasspass | |
02/8/2020 06:07 | Keep an eye on stock market minnow OKYO Pharma in the coming days. The talk is that OKYO Pharma's treatment could compete with the likes of Restasis, which is owned by drugs giant Allergan. | solidpink71 | |
31/7/2020 22:29 | You will probably wish you bought more soon. | albert arthur | |
31/7/2020 18:30 | Buyers paying x 10 what I paid on 29 May.Need the odd winner in a portfolio these days. GLA | bibs | |
30/7/2020 18:09 | Think we will see 20p here pretty quickly. | albert arthur | |
30/7/2020 00:38 | Well I have just been put right off buying IQAI | hope67 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions